Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)

[1] Chen XS(2014)Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis PLoS One 9 2278-2284

[2] Yuan Y(2013)Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Ann Oncol 24 164-172

[3] Garfield DH(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 27-39

[4] Wu JY(2018)Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Lancet Oncol 19 1700-1712

[5] Huang O(2017)De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Ann Oncol 28 13-30

[6] Shen KW(2001)MR imaging of the breast for the detection, diagnosis, and staging of breast cancer Radiology 220 924-931

[7] Schneeweiss A(2017)Clinical accuracy of preoperative breast MRI for breast cancer J Surg Oncol 115 1631-1638

[8] Chia S(2014)Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment Eur J Radiol 83 1177-1187

[9] Hickish T(2017)Neoadjuvant chemotherapy with MRI monitoring for breast cancer Br J Surg 104 1776-1783

[10] Harvey V(2013)Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017 Cancer 119 152-333

[1] Chen XS(2014)Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis PLoS One 9 2278-2284

[2] Yuan Y(2013)Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Ann Oncol 24 164-172

[3] Garfield DH(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 27-39

[4] Wu JY(2018)Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Lancet Oncol 19 1700-1712

[5] Huang O(2017)De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Ann Oncol 28 13-30

[6] Shen KW(2001)MR imaging of the breast for the detection, diagnosis, and staging of breast cancer Radiology 220 924-931

[7] Schneeweiss A(2017)Clinical accuracy of preoperative breast MRI for breast cancer J Surg Oncol 115 1631-1638

[8] Chia S(2014)Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment Eur J Radiol 83 1177-1187

[9] Hickish T(2017)Neoadjuvant chemotherapy with MRI monitoring for breast cancer Br J Surg 104 1776-1783

[10] Harvey V(2013)Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017 Cancer 119 152-333